Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Daewon Pharmaceutical Co., Ltd.

Clinicaltrial registered12 Nov 2026

Daewon Pharmaceutical Co., Ltd.

12 Nov 2026: Trial registered · Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease
Conditions
Erosive Reflux Disease, GERD (Gastroesophageal Reflux Disease)
Phase
Phase 3
Study Type
Interventional
Status
Completed
Countries
South Korea
Country
South Korea
Reference
NCT07931521
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Daewon Pharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.